Received Mar 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 1 | 943187 | IM / LA |
Received First Dose of HEPLISAV-B on 09/10/2024 and Second Dose of the Series Engerix-B on 10/10/2024; Initial report received on 10-Mar-2025. A pharmacist reported that a female patient received HEPLISAV-B (hepatitis B vaccine) for the first dose of hepatitis B immunization and received ENGERIX-B for the second dose of the series. Medical history included an allergy to amoxicillin (unknown reaction). No concomitant medications were reported. On 10-Sep-2024, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot number 943187, expiration date 30-Nov-2025, and NDC 43528-003-05)] intramuscularly in the left deltoid. On 10-Oct-2024, 31 days after receiving HEPLISAV-B, the patient received dose 2 of a hepatitis B vaccine [ENGERIX-B (lot number, expiration date, route, and site not available)]. The patient had no side effects. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.
Allergy to antibiotic (Unknown reaction)
Engerix b